Boston Scientific Unveils Early Taxus Sales Data; Cordis Looks Long-Term

Taxus appears to have bolted out of the gate, based on Boston Scientific's March 22 report that the paclitaxel-eluting stent has achieved about 80% of its low-end sales goal in less than half the time predicted